Form 4: Intuitive Surgical Executive Robert DeSantis Executes Stock Options Under 10b5-1 Trading Plan
SEC Form 4 Filing
Robert DeSantis, EVP & Chief Strategy & Corp Op at Intuitive Surgical, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.
Summary
- Robert DeSantis, an executive at Intuitive Surgical, executed stock options and sold shares of common stock on August 26, 2024.
- The transactions were conducted under a pre-arranged trading plan that complies with SEC Rule 10b5-1.
- DeSantis exercised options to acquire 198 shares at $245.6 and another 198 shares at $347.4167.
- He then sold 198 shares at $486.88 and another 198 shares at $486.88.
- Following these transactions, DeSantis directly owns 5,506 shares of Intuitive Surgical common stock.
- He also holds options to purchase 1,191 shares at $245.6 and another 1,191 shares at $347.4167.
Sentiment
Score: 5
Explanation: Neutral sentiment as the document simply reports stock transactions by an executive under a pre-existing trading plan. There is no indication of positive or negative implications for the company.
Positives
- The transactions were conducted under a pre-arranged 10b5-1 trading plan, which provides a defense against insider trading allegations.
Future Outlook
The executive's trading activity will continue to be governed by the 10b5-1 trading plan until its expiration on December 9, 2024.
Industry Context
Executive stock transactions are common in publicly traded companies and are often conducted under pre-arranged trading plans to avoid insider trading concerns. These transactions can provide insights into management's perspective on the company's value, but should be viewed in the context of individual financial planning.
Comparison to Industry Standards
- Executive compensation practices, including stock options and trading plans, are standard across the medical device industry.
- Companies like Medtronic, Stryker, and Johnson & Johnson also utilize stock options as part of their executive compensation packages.
- The vesting schedules and exercise prices of these options are generally aligned with industry norms to incentivize long-term performance.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the effect is likely minimal given the relatively small number of shares involved.
- Employees are unlikely to be directly affected by these transactions.
Key Dates
| Date | Description |
|---|---|
| July 25, 2024 | Date of Power of Attorney execution. |
| August 26, 2024 | Date of stock option exercise and sale transactions. |
| February 26, 2031 | Expiration date of Non-Qualified Stock Option (right to buy) at $245.6. |
| August 26, 2031 | Expiration date of Non-Qualified Stock Option (right to buy) at $347.4167. |
| December 9, 2024 | Expiration date of the 10b5-1 trading plan. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.